A Study of LY3415244 in Participants With Advanced Solid Tumors
The goal of this study is to evaluate the safety of LY3415244 administered as monotherapy to participants with advanced solid tumors.
Participation in this trial will last at least 8 weeks and possibly longer if your disease does not progress.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have an advanced solid tumor confirmed by histology or cytology
Participant must be willing to provide a newly obtained biopsy prior to and during study
Participant must have an estimated life expectancy of at least 12 weeks
Participant must not have symptoms of uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease that requires treatment occurring at the same time as the study treatment
Participant must not have received a live vaccine within 30 days before the first dose of study treatment
Female participant must not be pregnant, breastfeeding, or planning to become pregnant
Participant must not have active or chronic HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment
Participant must not have a bowel obstruction
Participant must not have moderate to severe cardiovascular disease